A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Completed
Arcus Biosciences, Inc.
Phase 1
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the
safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of
etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in
participants with advanced malignancies.
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Completed
Infinity Pharmaceuticals, Inc.
Phase 1
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the
safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of
etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or
without IPI-549 in participants with advanced metastatic triple-negative breast cancer (TNBC)
or ovarian cancer, and etrumadenant in combination with nanoparticle albumin-bound-paclitaxel
(NP) in participants with advanced metastatic TNBC.
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Completed
Arcus Biosciences, Inc.
Phase 1
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the
safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of
etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or
without IPI-549 in participants with advanced metastatic triple-negative breast cancer (TNBC)
or ovarian cancer, and etrumadenant in combination with nanoparticle albumin-bound-paclitaxel
(NP) in participants with advanced metastatic TNBC.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
